Evidence map›Paper›PMID 38955401›Full record

ArticleGut2024

Pancreatic STAT5 activation promotes Kras

Yuli Lin, Shaofeng Pu, Jun Wang, Yaqi Wan, Zhihao Wu, Yangyang Guo, Wenxue Feng, Ying Ying, Shuai Ma, Xiang Jun Meng and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Liver Kinase B1 in CD11cAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Reinvigorating COTL1Nature cell biology · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. STAT5: Understanding the Biology of KRASJournal of cellular and molecular medicine · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Yuli Lin *Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China yulilin@fudan.edu.cn xiaqing@shsmu.edu.cn xuguangyang11@fudan.edu.cn.ORCID 0000-0002-8779-2471
Shaofeng Pu *Pain Management Center, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, Shanghai, China.
Jun Wang *Department of general surgery, Huashan Hospital, Fudan University, Shanghai, Shanghai, China.
Yaqi Wan *Center for Medical Research and Innovation, Shanghai Pudong Hospital; Department of Immunology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, People's Republic of China.
Zhihao WuLonghua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China.
Yangyang GuoCenter for Medical Research and Innovation, Shanghai Pudong Hospital; Department of Immunology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, People's Republic of China.
Wenxue FengCenter for Medical Research and Innovation, Shanghai Pudong Hospital; Department of Immunology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, People's Republic of China.
Ying YingDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China.
Shuai MaDivision of Nephrology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, Shanghai, China.
Xiang Jun MengDepartment of Gastroenterology, Center for Digestive Diseases Research and Clinical Translation, Shanghai Key Laboratory of Gut Microecology and Associated Major Diseases Research, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China.ORCID 0000-0001-9657-0021
Wenquan WangDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China.
Liang LiuDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China.
Qing XiaDepartment of Biliary-Pancreatic Surgery, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China yulilin@fudan.edu.cn xiaqing@shsmu.edu.cn xuguangyang11@fudan.edu.cn.
Xuguang YangLonghua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China yulilin@fudan.edu.cn xiaqing@shsmu.edu.cn xuguangyang11@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy because it is often diagnosed at a late-stage. Signal transducer and activator of transcription 5 (STAT5) is a transcription factor implicated in the progression of various cancer types. However, its role in KRAS-driven pancreatic tumourigenesis remains unclear.

designWe performed studies with

resultsThe expression and phosphorylation of STAT5 were higher in human PDAC samples than control samples and high levels of STAT5 in tumour cells were associated with a poorer prognosis. The loss of STAT5 in pancreatic cells substantially reduces the KRAS mutation and pancreatitis-derived acinar-to-ductal metaplasia (ADM) and PDAC lesions. Mechanistically, we discovered that STAT5 binds directly to the promoters of ADM mediators, hepatocyte nuclear factor (HNF) 1β and HNF4α. Furthermore, STAT5 plays a crucial role in maintaining energy metabolism in tumour cells during PDAC progression. IL-22 signalling induced by chronic inflammation enhances KRAS-mutant-mediated STAT5 phosphorylation. Deficiency of IL-22 signalling slowed the progression of PDAC and ablated STAT5 activation.

conclusionCollectively, our findings identified pancreatic STAT5 activation as a key downstream effector of oncogenic KRAS signalling that is critical for ADM initiation and PDAC progression, highlighting its potential therapeutic vulnerability.

Indexed as

Carcinoma, Pancreatic DuctalMetaplasiaPancreatic NeoplasmsPancreatitisProto-Oncogene Proteins p21(ras)STAT5 Transcription FactorAcinar CellsAnimalsHumansMicePancreasHras protein, mouseProto-Oncogene Proteins p21(ras)STAT5 Transcription FactorENERGY METABOLISMINFLAMMATIONPANCREATIC CANCER

Identifiers

PMID38955401
PMCPMC11503187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.